Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

2(33.3%)

Phase 1

1(16.7%)

6Total

N/A(3)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04870437Not ApplicableRecruiting

Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation.

Role: collaborator

NCT07434869Not Yet Recruiting

Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD

Role: collaborator

NCT05157581Recruiting

Extracorporeal Photopheresis in Sezary Syndrome

Role: collaborator

NCT04291261Phase 2Active Not Recruiting

Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease

Role: collaborator

NCT00157027Phase 1Withdrawn

RHIV A Pilot Study Refractory or Intolerant to Highly Active Antiretroviral Therapy (HAART)

Role: collaborator

NCT00157001Phase 2Terminated

Feasibility Study of Photopheresis Post Angioplasty

Role: collaborator

NCT00502554Not ApplicableTerminated

Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation

Role: collaborator

NCT00002011Not ApplicableCompleted

The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex

Role: lead

All 8 trials loaded